TREANDA is a uniquely designed agent

TREANDA may cause dual cell death via multiple pathways^1-4

TREANDA is active against both quiescent and dividing cells

• The exact mechanism of action of TREANDA remains unknown

Bendamustine has been used in over 67,000 patients in the US and Europe since 1994⁵

TREANDA has a novel dual structure

TREANDA was synthesized as a unique chemical structure combining an alkylating group with a purine-like benzimidazole ring in 1963⁵

• The alkylating group contains mechlorethamine, which confers alkylating properties
• The benzimidazole component contains a purine-like benzimidazole ring

Indications

TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

• Serious adverse reactions, including myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies, and extravasation, have been associated with TREANDA. Some reactions, such as myelosuppression, infections, and SJS/TEN (when TREANDA was administered concomitantly with allopurinol and other medications known to cause SJS/TEN), have been fatal. Patients should be monitored closely for these reactions and treated promptly if any occur
  
  
• Adverse reactions may require interventions such as decreasing the dose of TREANDA, or withholding or delaying treatment
  
  
• TREANDA is contraindicated in patients with a known hypersensitivity to bendamustine or mannitol. Women should be advised to avoid becoming pregnant while using TREANDA
  
  
• The most common non-hematologic adverse reactions associated with TREANDA (frequency ≥30%) were nausea, fatigue, vomiting, diarrhea, and pyrexia. The most common hematologic abnormalities associated with TREANDA (frequency ≥15%) were lymphopenia, leukopenia, anemia, neutropenia, and thrombocytopenia

TO REPORT SIDE EFFECTS: Contact us at 1-800-896-5855 or usmedinfo@cephalon.com